Study of SRF617 in Patients With Advanced Solid Tumors

Advanced Solid Tumor Clinical Trial

Official title:

A Phase 1 Study of SRF617 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04336098
• Other study ID #: SRF617-101
• Secondary ID: KEYNOTE-A62MK-34
• Status: Completed
• Phase: Phase 1
• Start date: March 16, 2020
• Est. completion date: August 25, 2023

Study information

• Verified date: June 2024
• Source: Coherus Biosciences, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.

Description:

A Phase 1, open-label, first-in-human, study of SRF617, consisting of a monotherapy dose escalation, a monotherapy tumor biopsy expansion, combination dose escalations, and combination safety and efficacy expansions that will enroll patients with advanced solid tumors. The monotherapy dose escalation portion of the study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of SRF617 as monotherapy in patients with advanced solid tumors. The monotherapy tumor biopsy expansion portion of the study will further evaluate the safety and intratumoral pharmacodynamics of SRF617 monotherapy. The combination therapy dose escalation portion of the study will evaluate the safety, tolerability, PK, and preliminary efficacy of SRF617 in combination with gemcitabine + albumin-bound paclitaxel, or SRF617 in combination with pembrolizumab, in patients with locally advanced or metastatic solid tumors. Once the SRF617 combination recommended Phase 2 doses are established, additional patients with select solid tumors may be enrolled in the respective combination expansion arm of the study. An additional quadruplet combination will also be explored in patients with advanced first line (1L) PDAC (i.e., SRF617 + pembrolizumab + gemcitabine + albumin-bound paclitaxel).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 85
• Est. completion date: August 25, 2023
• Est. primary completion date: August 25, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Abbreviated Inclusion Criteria:

1. Be = 18 years of age on day of signing the informed consent

2. Experienced disease progression during or after standard therapy or were intolerant of standard therapy, and for whom no appropriate therapies are available (based on the judgment of the Investigator). (Exception: PDAC patients in 1L combination expansion arms.)

3. Histological or cytological evidence of advanced, relapsed, or refractory solid tumor cancer that is not a candidate for curative therapy

4. For all patients in the combination expansion arms, have at least 1 lesion that is measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by local site Investigator/radiology. The measurable lesion must be outside of a radiation field if the participant received prior radiation. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.

5. Have tumor tissue that is accessible for pretreatment and on treatment biopsy in the opinion of the Investigator and be willing to undergo pretreatment and on-treatment biopsies per protocol (for patients in the monotherapy tumor biopsy expansion arm only).

6. Adequate renal function

7. Total bilirubin = 1.5 x upper limit of normal (ULN) (= 3 x ULN if elevated because of Gilbert's syndrome); patients to be treated with SRF617 in combination with albumin-bound paclitaxel must have total bilirubin = 1.5 × ULN)

8. Aspartate aminotransferase and alanine aminotransferase < 2.5 x ULN (< 5 x ULN if liver metastasis is present)

9. Adequate hematologic function, defined as absolute neutrophil count (ANC) = 1.0 x 109/L, hemoglobin = 8.0 g/dL, and platelet count = 75 x 109/L. Blood cell transfusion to meet enrollment criteria is not allowed

10. Prothrombin time (PT) or international normalized ratio (INR) and activated partial thromboplastin time (aPTT) =1.5 × ULN unless the patient is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants

11. Eastern Cooperative Oncology Group performance status of 0 to 1

12. For the SRF617 + gemcitabine + albumin-bound paclitaxel expansion arm and SRF617 + pembrolizumab + gemcitabine + albumin-bound paclitaxel quadruplet expansion arm enrolling patients with 1L PDAC only:

1. Patients with confirmed advanced PDAC naive to any prior systemic treatment

2. Prior neoadjuvant or adjuvant therapy for PDAC is permitted if neoadjuvant or adjuvant therapy was completed at least 6 months prior to study enrollment. Prior pembrolizumab treatment is not allowed if patient is enrolling in the quadruplet expansion arm.

3. Patients initially diagnosed with locally advanced PDAC who have undergone chemotherapy then resection and had no evidence of disease are eligible if relapsed or metastatic disease has occurred and if the last dose of chemotherapy was received more than 6 months before study entry

13. For the anti-PD-(L) 1 naïve SRF617+ pembrolizumab combination expansion arm only:

1. Patients with unresectable locally advanced or metastatic HER2 GEJ who have received a maximum of 2 prior lines of anticancer therapy

2. Patients must be anti PD(L)-1 treatment naïve

14. For the anti-PD-(L) 1 relapsed/refractor SRF617 + pembrolizumab expansion arm only:

1. Patients with unresectable locally advanced or metastatic HER2- GC or GEJ adenocarcinoma or unresectable advanced or metastatic NSCLC whose disease is PD-L1+ (defined as CPS = 1 or TPS = 1%).

2. Must have received at least 1 prior line of systemic anticancer therapy and no more than 4 prior lines of systemic anticancer therapy

3. Must have anti-PD-(L) 1 relapsed/refractory diseased defined as having progressed on treatment and with anti-PD-(L)1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other immune checkpoint inhibitors or other therapies.

15. Willingness of male and female patients who are not surgically sterile or postmenopausal to use medically acceptable methods of birth control for the duration of the study treatment period (or beginning 14 days before the initiation of pembrolizumab for oral contraception), including 30 days after the last dose of SRF617, or 120 days after the last dose of pembrolizumab for patients in the pembrolizumab combination arms; male patients must refrain from donating sperm during this period. Sexually active men, and women using oral contraceptive pills, should also use barrier contraception with spermicide. Azoospermic male patients and women of child-bearing potential (WCBP) who are continuously not heterosexually active are exempt from contraceptive requirements; however, female patients must still undergo pregnancy testing as described in this section.

Abbreviated Exclusion Criteria:

1. Previously received an anti-CD39 antibody or anti-CD39 targeted therapy. In combination expansion arms, patients cannot have previously received agents that inhibit CD73, A2AR, or A2BR.

2. History of Grade 3 allergic or anaphylactic reaction to any monoclonal antibody therapy (mAb), or any excipient in the study drugs

3. Major surgery within 4 weeks before Screening

4. Unstable or severe uncontrolled medical condition (eg, unstable cardiac function, unstable pulmonary condition including pneumonitis and/or interstitial lung disease, uncontrolled diabetes) or any important medical illness or abnormal laboratory finding that would, in the Investigator's judgment, increase the risk to the patient associated with his or her participation in the study

5. For patients in the anti-PD-(L) 1 naïve SRF617 + pembrolizumab combination expansion arm only:

1. Discontinuation from previous therapy with an anti programmed cell death ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or co inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX 40, CD137) due to a = Grade 3 immune-related AE

2. Prior therapy with anti-PD-1 or anti-PD-L1 agents is not permitted

6. Currently participating in or has participated in a study of an investigational agent or has used an investigational device within 21 days before the first dose of study drug Note: Patients who have entered the follow-up phase of an investigational study may participate if it has been at least 21 days after the last dose of the previous investigational agent

7. Received prior radiotherapy within 2 weeks of start of study treatment. Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (= 2 weeks of radiotherapy) to non-central nervous system disease.

8. Has received radiation therapy to the lung that is >30Gy within 6 months of the first dose of study treatment

9. Current pneumonitis or history of (non-infectious) pneumonitis requiring steroids

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Neoplasms

Intervention

Drug:
• SRF617
SRF617 prevents CD39 mediated conversion of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP) and phosphate, leading to an increase in extracellular ATP and a reduction in adenosine levels within the tumor microenvironment (TME). There is an important role for extracellular ATP and adenosine in cancer maintenance and progression, and maintaining high levels of ATP (and low levels of adenosine) in the TME may have anticancer therapeutic activity.
• Gemcitabine
Gemcitabine as an intravenous (IV) infusion
• Albumin-Bound Paclitaxel
Albumin-bound paclitaxel as an IV infusion
• Pembrolizumab
Pembrolizumab as an IV infusion .

Locations

Country	Name	City	State
Canada	Universite de Montreal - Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopital Notre-Dame	Montréal	Quebec
Canada	University Health Network-Princess Margaret Cancer Centre	Toronto	Ontario
United States	University of Colorado	Aurora	Colorado
United States	University of Virginia	Charlottesville	Virginia
United States	Mary Crowley Cancer Research	Dallas	Texas
United States	City of Hope	Duarte	California
United States	The Angeles Clinic and Research Institute	Los Angeles	California
United States	South Texas Accelerated Research Therapeutics	San Antonio	Texas
United States	University of Washington	Seattle	Washington
United States	Moffitt Cancer Center	Tampa	Florida

Sponsors (3)

Lead Sponsor	Collaborator
Coherus Biosciences, Inc.	Merck Sharp & Dohme LLC, Surface Oncology

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose Limiting Toxicity of SRF617	Evaluation of dose-limiting toxicity (DLT).	Assessed during first 28 days of treatment
Secondary	Safety Analysis: Summary of adverse events (AEs) and based on treatment-emergent AEs (TEAEs)	Safety and tolerability of SRF617 monotherapy and combination therapy will be assessed by summarizing adverse events (AEs) and will be based on treatment-emergent AEs (TEAEs). A TEAE is an AE that emerges or worsens in the period from the first dose of study drug to 30 days after the last dose of study drug assessed by per CTCAE version 5.0 or higher.	Up to 24 months
Secondary	Pharmacokinetics (PK) of SRF617	Serum concentrations of SRF617 will be collected and analyzed to evaluate the PK of SRF617.	Up to 24 months
Secondary	Pharmacodynamics of SRF617	Pharmacodynamics of SRF617 will be evaluated via serum target occupancy.	Up to 24 months
Secondary	Objective response rate (ORR)	ORR will be estimated by the percentage of patients achieving a best overall response of CR or PR per iRECIST.	Up to 24 months
Secondary	Duration of response (DoR)	DoR is defined as the time from the first documented response (CR or PR) to documented disease progression as determined by applicable disease criteria, or documented death due to any cause, whichever occurs first.	Up to 24 months
Secondary	Disease control rate (DCR)	DCR is defined as the percentage of patients with CR, partial PR, or stable disease lasting a minimum of 12 weeks.	Up to 24 months
Secondary	Progression-free survival (PFS)	PFS is defined as the time from the first treatment on study with study drug to documented disease progression as determined by applicable disease criteria or death.	Up to 24 months
Secondary	Landmark PFS rate	Landmark PFS is defined as the percentage of patients who have not developed PFS events (ie, death or documented disease progression as determined by applicable disease criteria) at 6 months, 1 year, 1.5 years, and 2 years.	Up to 24 months
Secondary	Effect of SRF617 on intratumoral CD39 enzymatic activity	Levels of intratumoral CD39 enzymatic activity will be evaluated in patients receiving pretreatment and on-treatment tumor biopsies via an in situ ATPase histochemistry assay.	Up to 24 months